Other languages Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Market Closed - Nasdaq Other stock markets 21:00:00 26/04/2024 BST			5-day change	1st Jan Change
29.32 ^USD	+1.35%		-0.27%	-9.23%

04-11	Harmony Biosciences, Bioprojet Enter Licensing Deal for Sleep Disorder Therapy	MT
04-03	Harmony Biosciences Begins Phase 3 Trial of Pitolisant to Treat Prader-Willi Syndrome Symptoms	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Harmony Biosciences, Bioprojet Enter Licensing Deal for Sleep Disorder Therapy	04-11
Harmony Biosciences Begins Phase 3 Trial of Pitolisant to Treat Prader-Willi Syndrome Symptoms	04-03
Harmony Biosciences Initiates Global Phase 3 Registrational Trial (Tempo Study) of Pitolisant in Patients with Prader-Willi Syndrome	04-03
Harmony Biosciences Holdings Insider Sold Shares Worth $383,328, According to a Recent SEC Filing	03-19
Harmony Biosciences Holdings' Q4 Adjusted Net Income Falls, Net Product Revenue Rises; 2024 Revenue Guidance Issued	02-22
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-22
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22
Harmony Biosciences Holdings, Inc. Provides Revenue Guidance for the Year 2024	02-22
Harmony Biosciences Says FDA Grants Priority Review for Wakix Supplemental New Drug Application	02-21
U.S. Food and Drug Administration Grants Priority Review to Harmony Biosciences' Application for WAKIX® in Pediatric Narcolepsy	02-21
Harmony Biosciences' Pitolisant Gets FDA's Orphan Drug Designation for Prader-Willi Syndrome	02-20
Harmony Biosciences Preliminary Q4 Results Show "Robust Momentum" for Narcolepsy-Related Drug, Oppenheimer Says	01-10
Harmony Biosciences Reports Higher Preliminary Q4 Revenue; Sets 2024 Revenue Outlook	01-08
Harmony Biosciences Holdings, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year 2023 and for the Year 2024	01-08
Harmony Biosciences Holdings, Inc. Announces Positive Topline Data from Phase 2 Signal Detection Study Evaluating Pitolisant in Adult Patients with Myotonic Dystrophy Type 1	12-07
Harmony Biosciences Holdings, Inc. Appoints Peter Anastasiou as Class III Director and Member of the Compensation Committee of the Board	11-08
Harmony Biosciences Holdings' Q3 Non-GAAP Earnings, Revenue Rise	31/10/23
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	31/10/23
Harmony Biosciences Holdings, Inc. announces an Equity Buyback for $200 million worth of its shares.	31/10/23
Harmony Biosciences Holdings, Inc. authorizes a Buyback Plan.	26/10/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Other languages

Filters